News

The upcoming phase 2b/3 study of mesdopetam in patients with Parkinson disease is set after the results of previous successful phase 1, phase 2a, and phase 2 studies.

The 5-year grant will support a research project that will use biomarkers to develop a predictive mathematical model to identify specific individuals with Parkinson disease who may develop dementia.

Patients treated with Axovant’s gene therapy AXO-Lenti-PD reported improvements of 40% in UPDRS-III scores, and 71% improvement in activities of daily living.

Nearly two-thirds of patients achieved developmental motor milestones not observed in the natural history of SMA Type 1 at a mean duration of follow-up of 10.6 months.

Sucheta M. Joshi, MD, MS, and Nicholas Beimer, MD, outline how EpiTRAQ may be incorporated in future studies and what outcomes may be observed.

James Leverenz, MD, director of the Lou Ruvo Center for Brain Health at Cleveland Clinic, discussed the strides made in Alzheimer disease research and the importance of diversity in research populations.

Linear mixed effects models revealed that anticholinergic medications predicted a steeper slope of decline in memory and language with effects exacerbated in individuals with Alzheimer disease risk factors.

The postdoctoral research fellow in the Dystonia and Speech Motor Control Laboratory at Mass Eye and Ear spoke to the clinical translation of the AI-based DystoniaNet tool.

Results from a 24-week phase 2a trial and its 2-year extension suggest that patients taking vamorolone experienced motor outcome improvements compared to corticosteroid-naïve individuals.

The director of Laryngology Research at Mass Eye and Ear discussed how the AI-based DystoniaNet came to be and what challenges impact the diagnosis of dystonia.

The Clinical Global Impression of Change and Caregiver Global Impression of Change scores suggest improvements extending beyond motor seizure frequency reduction in both patients with CDD and Dup15q.

Julio J. Fernandez-Mendoza, PhD, a clinician-scientist at Penn State Hershey Sleep Research & Treatment Center, of Penn State Health, spoke to the implications of a recent study he and colleagues conducted.

Advanced imaging shows Parkinson disease can begin as brain-first or body-first.

Here's what is coming soon to NeurologyLive.

Solid Biosciences noted that its response to the agency requests for further information about manufacturing as well as updated safety and efficacy data on all dosed patients led to the lift.

The director of the Parkinson’s Foundation Center for Excellence at the University of Kansas Medical Center provided insight on the lapses in levodopa-carbidopa treatment and what potential changes could come in the future.

The results confirmed that roughly almost 15% of cases are linked to genes and ultimately led to recommendations for more tailored treatments of 3 patients.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending October 2, 2020.

Jonathan Graff-Radford, MD, neurologist at Mayo Clinic, discussed how recent diagnostic advancements have propelled research efforts into uncharted territory.

The use of statins was also associated with a reduced risk of SUDEP, but there were no reduced risks with SSRIs or other antidepressants, neuroleptics, or beta-blockers.

The free webcast programs, which will focus on cannabis use in MS and MS nursing care, will earn participants up to 3 CE credits each.

The director of the Parkinson’s Foundation Center for Excellence at the University of Kansas Medical Center shared the reasons why LCIG is underused in clinical care.

Zosano Pharma noted that the DRL does not reflect the final FDA decision on the application, though the approval of zolmitriptan by its PDUFA action date of October 20, 2020, is no longer likely as a result.

The primary objective of the trial is to demonstrate that lorcaserin has superior efficacy compared to placebo as measured by percent change in frequency of convulsive seizures per 28 days.

The head of the Laboratory of Clinical Pharmacology and Therapeutics at the University of Lisbon gave his perspective on the importance of the study population of this analysis.

The findings were consistent with the drug's previously reported safety profile and no new safety signals were observed.

The investigators noted that continuous non-invasive blood pressure monitoring upon standing may aid in the identification of a modifiable risk factor for syncope-related falls in patients with Parkinson disease.

Volumetric MRI shows Hispanic patients are at a greater risk of experiencing more aggressive disease, leading to sustained disability.